Clinical Trial News and Research

RSS

GLP-1 therapy linked to slower biological aging processes

Glucagon-like peptide-1 (GLP-1) receptor agonist medications have gained widespread attention for effectively treating obesity, lowering blood sugar and decreasing the risk of cardiovascular disease.

2 Jun 2026

Modified stem cell therapy reverses new-onset Type 1 diabetes in mice

A group of researchers at the Medical University of South Carolina (MUSC) has recently developed a new stem cell therapy with a remarkable ability to reverse new-onset Type 1 diabetes (T1D) in a mouse model of the disease.

2 Jun 2026

Five-minute session of proximal intercessory prayer eases primary care pain and anxiety

A randomized controlled trial conducted at the University of Maryland School of Medicine has found that a five-minute session of proximal intercessory prayer (PIP) - in-person prayer offered by a trained volunteer - significantly reduced pain and anxiety in primary care patients compared to a music control group.

2 Jun 2026

First-in-class cancer drug gamitrinib evaluated in phase 1 clinical trial

Cancer cells need large amounts of energy to survive and multiply. To produce that energy, they rely on structures inside the cell called mitochondria, often described as the cell's "powerhouse."

2 Jun 2026

GLP-1 medications linked to lower breast cancer risk in women

A retrospective analysis of more than 110,000 women between the ages of 45 and 80 found that those who took GLP-1 medications were about 30 percent less likely to develop breast cancer than those who did not take GLP-1 medications, according to research presented today at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract 10506) by Elizabeth McDonald, MD, PhD, a professor of Radiology in the University of Pennsylvania Perelman School of Medicine and a practicing breast radiologist at Penn's Abramson Cancer Center.

2 Jun 2026

Most psoriasis patients can safely reduce their dosage of biologics

Three-quarters of people who respond well to the newest types of biologics for psoriasis can safely reduce their dosage, often even by half.

1 Jun 2026

Brazilian study links TP53 mutations to poor lung cancer prognosis

Lung cancer is the most common and deadly form of cancer worldwide. It is increasingly understood to be a complex genetic disease with different mutations that vary according to factors such as smoking and ethnicity.

1 Jun 2026

$2 million NIH funding supports wearable knee exoskeleton research

Building on the success of projects to boost strength by adding motors to conventional knee, hip and ankle braces, a University of Michigan team is exploring how well this approach could work for relieving knee pain from osteoarthritis.

1 Jun 2026

Pharmacist-led care delivering real results for women’s health

Pharmacy Guild of Australia, NSW Branch, today welcomed the release of new data from two NSW Government-sponsored clinical trials confirming allowing pharmacists to diagnose and treat uncomplicated urinary tract infections (UTIs) and providing resupply of oral contraception is delivering safe, effective care for women, while easing pressure on the health system and saving emergency departments millions of dollars.

1 Jun 2026

Apple Watch app detects seizures with 98% accuracy

The EpiWatch app shows high sensitivity in detecting tonic-clonic seizures in children and adults, potentially reducing SUDEP risk with timely alerts.

1 Jun 2026

New T-cell engager therapy shows effectiveness in advanced solid tumors

A team led by researchers from the National Center for Tumor Diseases (NCT/UCC) Dresden at the Carl Gustav Carus University Hospital (UKD) and the Carl Gustav Carus Faculty of Medicine at the TUD Dresden University of Technology will present clinical results for the first time on May 31, 2026, at this year’s annual meeting of the American Society of Clinical Oncology (ASCO) regarding a new cancer immunotherapy for the treatment of advanced tumors.

1 Jun 2026

High-risk prostate cancer patients benefit from perioperative apalutamide therapy

High-risk localized and locally advanced prostate cancer patients treated with apalutamide - a next generation neoadjuvant androgen-receptor pathway inhibitor (ARPI) - plus hormone therapy before and after prostate cancer surgery resulted in more major pathologic responses and reduced the risk of metastasis or death, meeting both primary endpoints, in an international phase 3 clinical trial led by principal investigator Mary-Ellen Taplin, MD, medical oncologist at Dana-Farber Cancer Institute, and Adam Kibel, MD, chair of the Department of Urology at Mass General Brigham.

31 May 2026

Daraxonrasib significantly extends survival in metastatic pancreatic cancer

At the ASCO annual meeting, Dana-Farber's Brian Wolpin, MD, MPH, will present positive results from the RASolute 302 trial showing a substantial prolongation of survival for patients with previously treated metastatic pancreatic cancer, regardless of RAS mutation status, taking daraxonrasib, an investigational oral RAS(ON) multi-selective inhibitor, compared with chemotherapy.

31 May 2026

Implanted collagen tiles double survival for brain metastasis patients

A multicenter clinical trial led by researchers at The University of Texas MD Anderson Cancer Center has found that implanting collagen tiles during brain surgery to deliver targeted radiation therapy dramatically improved tumor control, lowered the risk of recurrence and improved overall survival compared to current standard of care for patients with newly diagnosed brain metastases in need of surgical resection.

30 May 2026

Gene test helps many breast cancer patients avoid chemotherapy

Many people with breast cancer can safely avoid chemotherapy with the use of a gene test, potentially sparing them unnecessary side effects without increasing the risk of the cancer returning, a large international clinical trial led by UCL has found.

29 May 2026

Teclistamab delivers deeper responses in relapsed myeloma patients

Patients with relapsed multiple myeloma treated with the immunotherapy teclistamab lived significantly longer and remained in remission far longer than those receiving standard therapies, according to results from a major international phase 3 clinical trial published in The New England Journal of Medicine and presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.

29 May 2026

WHO prioritizes candidate vaccines and therapeutics for Bundibugyo virus

In response to the current outbreak of Ebola disease caused by Bundibugyo virus occurring in the Democratic Republic of the Congo, with cases also reported in Uganda, WHO convened several of its expert and advisory groups.

29 May 2026

Half of clinical trial professionals cite trust and regulatory gaps as barrier to AI adoption, Pistoia Alliance poll finds

The Pistoia Alliance, a global, not-for-profit alliance that advocates for greater collaboration in life sciences R&D, has released new poll data showing trust and regulatory uncertainty are the biggest barriers to AI adoption in clinical trials, cited by half of respondents (50 %).

29 May 2026

Advanced tau imaging improves early Alzheimer’s disease detection accuracy

A new brain imaging test can detect a key hallmark of Alzheimer's disease before symptoms appear and earlier than the method currently used in clinical practice in the United States and Europe, report University of Pittsburgh School of Medicine researchers today in The Lancet.

28 May 2026

Ocrelizumab slows disability progression in advanced progressive multiple sclerosis

A major international phase III clinical trial, led by Queen Mary University of London, has found that ocrelizumab – a medication already prescribed to some patients with MS – significantly slows disability progression in people with primary progressive multiple sclerosis (PPMS), including older patients and those with more advanced disease who are wheelchair users.

28 May 2026